DukeUniversity chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.
Cancer surgeons today operate "blind" with no clear way of determining in real-time whether they have removed all of the diseased tissue, which is the key to successful surgery. Researchers in Massachusetts now report development and early clinical trials of a new imaging system that highlights cancerous tissue in the body so that surgeons can more easily see and remove diseased tissue with less damage to normal tissue near the tumor.
The pharmaceutical company Bristol-Myers Squibb (BMS) recently obtained approval in the American market for IXEMPRA, a semi-synthetic analog of epothilone B, for the treatment of patients with metastatic breast cancer resistant or refractory to anthracyclines, taxanes, and capecitabine.
The effective treatment of many forms of cancer continues to pose a major problem for medicine. Many tumours fail to respond to standard forms of chemotherapy or become resistant to the medication. Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, the Hannover Medical School (MHH) and Leibniz-Universität (LUH) in Hanover have now discovered a chemical mechanism with which a natural substance - argyrin - destroys tumours. Today, the researchers publish their findings in the renowned scientific journal "CancerCell".
A new discovery has been made in cancer research. Researchers from the Laboratoire des collisions atomiques et moléculaires (CNRS/Université Paris 11) and the Laboratoire Génotoxicologie et cycle cellulaire (CNRS/Institut Curie) were the first to show that it is possible to improve hadrontherapy's(1) targeting and destruction of tumor cells by loading the cells with heavy atoms like platinum. This new method enables both the treatment's effectiveness and the ions' ballistic effect to be improved without damaging healthy tissue.